ADMA Biologics appoints Eduardo Rene Salas to Board of Directors

ADMA BIOLOGICS, INC.

Appointed Eduardo Rene Salas as Class I director, term expiring at 2026 annual meeting.
Salas is former EY audit partner (2002-2019) and former CFO of Wellstat Therapeutics (2020-2022).
He currently serves on audit committee of Intra-Cellular Therapies (since 2022).
He will receive initial grant of options to purchase 20,011 shares of common stock.
No material transactions or arrangements in connection with appointment.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eduardo Rene Salas

Class I Director

ADMA · ADMA BIOLOGICS, INC.

Effective: 2024-12-30
Filed: January 2, 2025, 6:59 PM ET

On December 30, 2024, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Eduardo Rene Salas to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eduardo Rene Salas was appointed as Class I Director at ADMA BIOLOGICS, INC..

Action: appointed
Role: Class I Director

Exact text from the filing

On December 30, 2024, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Eduardo Rene Salas to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.

View on SEC.gov

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-25-000073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.